RESEARCH · NAD+ · AXON DEGENERATION AND SARM1
NAD+ and Axon Degeneration: NMNAT2, SARM1, the NMN-to-NAD+ Ratio and What Blocking the Pathway Shows
PurixLab’s NAD+ 500mg is a research vial of the coenzyme nicotinamide adenine dinucleotide. Our earlier articles cover NAD+ coenzyme biology, membrane transport, age-related decline in human tissue and how NAD+ is measured. This article follows a different thread: the axon. Since 2001, genetics, structural biology and metabolite measurements have converged on a pathway in which the balance between NAD+ and its precursor NMN decides whether an injured nerve fibre survives or self-destructs. These are findings from published laboratory and animal research; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.
A mouse that would not degenerate
Axons separated from their cell body normally break down rapidly, a process named Wallerian degeneration. The exception that opened the field was the Wallerian degeneration slow mouse. The protective gene turned out to encode an N-terminal fragment of ubiquitination factor E4B fused to nicotinamide mononucleotide adenylyltransferase, and its protective effect depended on how much of the protein was expressed: transected distal axons survived for two weeks and neuromuscular junctions were also protected. The protein sat mostly in the nucleus, suggesting an indirect mechanism, and NMNAT enzyme activity, but not NAD+ content, was increased fourfold in the mutant tissues; the authors proposed altered ubiquitination or pyridine nucleotide metabolism as the likely basis [1].
The endogenous counterpart followed. NMNAT2 behaved as a labile axon survival factor whose constant replenishment by anterograde axonal transport limits axon survival. Depleting NMNAT2 alone was enough to make uninjured axons degenerate in a Wallerian-like way, NMNAT1 and NMNAT3 could not substitute, and NMNAT2 disappeared from distal stumps before degeneration began; proteasome inhibition slowed both NMNAT2 turnover and neurite degeneration [2].
SARM1: the executioner
The other half of the pathway came from loss-of-function genetics. Removing the Drosophila Toll receptor adaptor dSarm suppressed Wallerian degeneration for weeks after axotomy, and severed mouse Sarm1-null axons survived long term both in vivo and in vitro, showing the program was conserved [3]. Using a protease-sensitised SARM1, later work showed that SARM1 activity is required after injury, that dimerisation of its Toll/interleukin-1 receptor (TIR) domain alone triggers local axon destruction, and that this is accompanied by rapid breakdown of NAD+ which increased NAD+ synthesis can counteract [4].
Then came the mechanism. Purified from mammalian cells, bacteria and a cell-free translation system, the SARM1 TIR domain was shown to be an enzyme in its own right: it cleaves NAD+ into ADP-ribose, cyclic ADP-ribose and nicotinamide, with nicotinamide acting as a feedback inhibitor, and this NADase activity is required in axons for injury-induced degeneration [5]. Steady-state and flux measurements of NAD+ metabolites in healthy and injured mouse dorsal root ganglion axons showed that overexpressed NMNAT1 protects not by making more NAD+ but by blocking this SARM1-dependent consumption [6].
Why NMN matters: a ratio, not a level
A parallel line of work asked what activates SARM1. NMN, the substrate that NMNAT2 converts to NAD+, accumulates after nerve injury. Inhibiting the NMN-synthesising enzyme NAMPT protected injured axons and synapses even though it lowered NAD+; added NMN abolished that protection, and expressing a bacterial NMN deamidase to scavenge NMN prolonged survival [7].
Structural biology tied the two observations together. Cryo-electron microscopy of full-length SARM1 revealed NAD+ as an unexpected ligand of the armadillo-repeat (ARM) domain, where its binding helps inhibit the TIR NADase through the domain interface; disrupting that site or the ARM-TIR interface produced constitutively active SARM1 and axon degeneration [8]. Structural, biochemical, biophysical and cellular assays then showed that NMN and NAD+ compete for binding to that autoinhibitory ARM domain, that SARM1 is activated by an increase in the ratio of NMN to NAD+, and that NMN binding is required for injury-induced activation [9]. The same allosteric site binds nicotinic acid mononucleotide, which competes with NMN, inhibits SARM1 activation and contributes to the long-term axon protection produced by combining the NAMPT inhibitor FK866 with nicotinic acid riboside, or by expressing NMN deamidase [10]. In mouse sympathetic neurons, disrupting mitochondrial membrane potential depleted axonal NMNAT2 and raised the NMN-to-NAD+ ratio; the slow Wallerian degeneration protein or Sarm1 deletion protected the axons, and blocking the pathway was neuroprotective and extended lifespan in flies carrying a Pink1 loss-of-function mutation [11].
What blocking the pathway does in animals
- Genetic axonopathy. In NMNAT2-deficient mice, both Sarm1 deletion and the slow Wallerian degeneration protein rescue perinatal lethality, but only the Sarm1-null animals survived into old age with no overt phenotype; those rescued by the mutant protein developed a progressive hindlimb neuromuscular defect from around 3 months [12].
- Chemotherapy and metabolic models. Deleting Sarm1 blocked the mechanical and heat hyperalgesia, loss of tail nerve action potential amplitude and loss of nerve fibres caused by vincristine in mice [13], and Sarm1-null mice resisted distal axon degeneration in paclitaxel and high-fat-diet models [14].
- Trauma. After closed-head mild traumatic brain injury, Sarm1-null mice had fewer amyloid precursor protein aggregates in the corpus callosum, lower plasma phosphorylated neurofilament heavy chain and better early neurological function [15].
- Gene lowering. Protection is graded: lowering SARM1 levels by 50% in haploinsufficient mice already delayed degeneration after sciatic nerve transection, and antisense oligonucleotides that lowered levels by more than 50% delayed or prevented it in vitro [16].
From mouse to molecule and to human cells
Small molecules now exist. A potent, selective isoquinoline inhibitor of the SARM1 NADase reproduced the knockout phenotype and, strikingly, rescued axons that had already entered a metastable state after mitochondrial insult with rotenone [17]. A second, irreversible isothiazole series protected rodent and human axons in vitro, lowered nerve cyclic ADP-ribose and plasma neurofilament light after sciatic axotomy, and partly preserved nerve function in a paclitaxel model, where protection from Sarm1 knockout scaled with the number of Sarm1 copies removed [18]. Sensory neurons derived from two SARM1 knockout human induced pluripotent stem cell lines showed that the human protein is required for axon degeneration after physical trauma and in a cellular model of chemotherapy-induced neuropathy, and identified cyclic ADP-ribose as a readout of enzyme activity [19].
Human genetics adds a cautious hint. Seven rare missense or in-frame microdeletion SARM1 alleles that alter the ARM domain and constitutively hyperactivate the NADase were reported in patients with amyotrophic lateral sclerosis and other motor nerve disorders, with broad phenotypic heterogeneity and variable age of onset [20].
Reading this evidence critically
- Mostly cells and mice. The protection data are preclinical; no outcome trial of a SARM1 inhibitor is summarised here.
- One metabolite is not enough. NAMPT inhibition protected injured axons while lowering NAD+, and other protective treatments act partly by raising nicotinic acid mononucleotide, so protection cannot be read off a single NAD+ number [7,10].
- Claims get tested. A 2026 study using purified protein, biophysical assays, primary neurons and cellular pharmacology did not support the proposal that double-stranded DNA directly activates SARM1, found that DNA-induced NAD+ depletion in cells ran through PARP-dependent pathways independently of SARM1, and reported that the proposed DNA-binding mutant is nonfunctional in canonical activation paradigms such as axotomy [21].
What remains open
- Whether the metastable, rescuable axon state seen in culture exists in chronic human neuropathy [17].
- How hyperactive SARM1 variants cause disease, given the broad phenotypic heterogeneity and variable age of onset among carriers [20].
NAD+ 500mg at PurixLab
NAD+ 500mg: a labelled lyophilized research vial with 500mg per vial, C$109 per vial (CAD, before tax), supplied for laboratory research only. NAD+ is a coenzyme, not a peptide. Batch documentation is available on request. Product page: purixlab.com/product/nad-500mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Mack TG, Reiner M, Beirowski B, et al. Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nat Neurosci. 2001;4(12):1199-206. PubMed 11770485 · doi:10.1038/nn770
- Gilley J, Coleman MP. Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons. PLoS Biol. 2010;8(1):e1000300. PubMed 20126265 · PMC2811159 · doi:10.1371/journal.pbio.1000300
- Osterloh JM, Yang J, Rooney TM, et al. dSarm/Sarm1 is required for activation of an injury-induced axon death pathway. Science. 2012;337(6093):481-4. PubMed 22678360 · PMC5225956 · doi:10.1126/science.1223899
- Gerdts J, Brace EJ, Sasaki Y, et al. SARM1 activation triggers axon degeneration locally via NAD⁺ destruction. Science. 2015;348(6233):453-7. PubMed 25908823 · PMC4513950 · doi:10.1126/science.1258366
- Essuman K, Summers DW, Sasaki Y, et al. The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration. Neuron. 2017;93(6):1334-1343.e5. PubMed 28334607 · PMC6284238 · doi:10.1016/j.neuron.2017.02.022
- Sasaki Y, Nakagawa T, Mao X, et al. NMNAT1 inhibits axon degeneration via blockade of SARM1-mediated NAD+ depletion. Elife. 2016;5:e19749. PubMed 27735788 · PMC5063586 · doi:10.7554/eLife.19749
- Di Stefano M, Nascimento-Ferreira I, Orsomando G, et al. A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration. Cell Death Differ. 2015;22(5):731-42. PubMed 25323584 · PMC4392071 · doi:10.1038/cdd.2014.164
- Jiang Y, Liu T, Lee CH, et al. The NAD+-mediated self-inhibition mechanism of pro-neurodegenerative SARM1. Nature. 2020;588(7839):658-663. PubMed 33053563 · doi:10.1038/s41586-020-2862-z
- Figley MD, Gu W, Nanson JD, et al. SARM1 is a metabolic sensor activated by an increased NMN/NAD+ ratio to trigger axon degeneration. Neuron. 2021;109(7):1118-1136.e11. PubMed 33657413 · PMC8174188 · doi:10.1016/j.neuron.2021.02.009
- Sasaki Y, Zhu J, Shi Y, et al. Nicotinic acid mononucleotide is an allosteric SARM1 inhibitor promoting axonal protection. Exp Neurol. 2021;345:113842. PubMed 34403688 · PMC8571713 · doi:10.1016/j.expneurol.2021.113842
- Loreto A, Hill CS, Hewitt VL, et al. Mitochondrial impairment activates the Wallerian pathway through depletion of NMNAT2 leading to SARM1-dependent axon degeneration. Neurobiol Dis. 2020;134:104678. PubMed 31740269 · PMC7611775 · doi:10.1016/j.nbd.2019.104678
- Gilley J, Ribchester RR, Coleman MP. Sarm1 Deletion, but Not WldS, Confers Lifelong Rescue in a Mouse Model of Severe Axonopathy. Cell Rep. 2017;21(1):10-16. PubMed 28978465 · PMC5640801 · doi:10.1016/j.celrep.2017.09.027
- Geisler S, Doan RA, Strickland A, et al. Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice. Brain. 2016;139(Pt 12):3092-3108. PubMed 27797810 · PMC5840884 · doi:10.1093/brain/aww251
- Turkiew E, Falconer D, Reed N, et al. Deletion of Sarm1 gene is neuroprotective in two models of peripheral neuropathy. J Peripher Nerv Syst. 2017;22(3):162-171. PubMed 28485482 · PMC5585053 · doi:10.1111/jns.12219
- Henninger N, Bouley J, Sikoglu EM, et al. Attenuated traumatic axonal injury and improved functional outcome after traumatic brain injury in mice lacking Sarm1. Brain. 2016;139(Pt 4):1094-105. PubMed 26912636 · PMC5006226 · doi:10.1093/brain/aww001
- Gould SA, Gilley J, Ling K, et al. Sarm1 haploinsufficiency or low expression levels after antisense oligonucleotides delay programmed axon degeneration. Cell Rep. 2021;37(11):110108. PubMed 34910914 · PMC8692746 · doi:10.1016/j.celrep.2021.110108
- Hughes RO, Bosanac T, Mao X, et al. Small Molecule SARM1 Inhibitors Recapitulate the SARM1-/- Phenotype and Allow Recovery of a Metastable Pool of Axons Fated to Degenerate. Cell Rep. 2021;34(1):108588. PubMed 33406435 · PMC8179325 · doi:10.1016/j.celrep.2020.108588
- Bosanac T, Hughes RO, Engber T, et al. Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathy. Brain. 2021;144(10):3226-3238. PubMed 33964142 · PMC8634121 · doi:10.1093/brain/awab184
- Chen YH, Sasaki Y, DiAntonio A, et al. SARM1 is required in human derived sensory neurons for injury-induced and neurotoxic axon degeneration. Exp Neurol. 2021;339:113636. PubMed 33548217 · PMC8171232 · doi:10.1016/j.expneurol.2021.113636
- Gilley J, Jackson O, Pipis M, et al. Enrichment of SARM1 alleles encoding variants with constitutively hyperactive NADase in patients with ALS and other motor nerve disorders. Elife. 2021;10:e70905. PubMed 34796871 · PMC8735862 · doi:10.7554/eLife.70905
- Kao AH, Mishra BP, Sorbello M, et al. Direct activation of SARM1 by dsDNA is not supported by biochemical and cellular evidence. Proc Natl Acad Sci U S A. 2026;123(37):e2620112123. PubMed 42726653 · PMC13578336 · doi:10.1073/pnas.2620112123